Almost all D3
of these involve some data analysis. In many ways, this whole pipeline is broken by bearing : =
such costs, or through the pricing of drugs that NICE will not afford. So in fact the present : =
process, imposed prior to licensing to protect citizens, is suffocating the industry and thereby :
putting citizens at risk. A creative way out of this is to have some pooling of information, sharing 8
of targets at early stages and this supported by public money alongside of multiple small and 7s
large corporations’ investment, with only later stages becoming protected and competitive, see 18

the ‘Bioescalator’ concept in [42], for example. About 10 years ago the UK financial sector became acutely aware that the high degree of
regulation had created barriers to new entrants to the retail banking sector.